TNF and inflammatory bowel disease: In patients with a diagnosis of IBD, either CD or UC, a biomarker assay to predict response to anti-TNFα treatment is needed because of potentially serious side effects of the treatment and significant treatment costs (D’Haens and Deventer, 2021).